Dupixent Gets Room To Grow With New Indication In Chronic Rhinosinusitis
The new indication represents the third one for Sanofi/Regeneron's IL-4/IL-13 inhibitor, after atopic dermatitis and moderate to severe asthma.
You may also be interested in...
Keeping Track: US FDA Closes Out First Half Of 2019 With CRL For Edsivo, But A Burst Of Supplemental Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Sanofi and Regeneron take a big step forward to building an allergy franchise off the back of newly released data from latest Dupixent trials in severe chronic rhinosinusitis with nasal polyps.